Orionis Biosciences Funding: $85M Raised, Series C (2022)
Orionis Biosciences is based in Waltham, Massachusetts. It has raised $85M in total funding. Latest round: Series C.
Orionis Biosciences funding overview
Orionis Biosciences is based in Waltham, Massachusetts. Orionis Biosciences has raised $85M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series C announced in October 2022. The round record for Orionis Biosciences runs through 2022; nothing later has been disclosed. Investors on record include Cormorant Asset Management, Novartis, Cascade Investment, Genentech, V-Bio Ventures, Excel Venture Management and 1 others. 7 distinct backers are named across the disclosed rounds.
Frequently asked about Orionis Biosciences funding
How much has Orionis Biosciences raised?
Orionis Biosciences has raised $85M in total disclosed funding across the rounds on record.
Who has invested in Orionis Biosciences?
Cormorant Asset Management, Novartis, Cascade Investment, Genentech, V-Bio Ventures, Excel Venture Management are named among the investors backing Orionis Biosciences.
What was the latest Orionis Biosciences funding round?
The most recent disclosed round is a Series C, announced in October 2022.
Where is Orionis Biosciences based?
Orionis Biosciences is based in Waltham, Massachusetts.
When did Orionis Biosciences last raise?
The last disclosed Orionis Biosciences round closed in October 2022 at Series C.
Round data for Orionis Biosciences is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the companies in Waltham and backer lists below.
